Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Francois Vergez"'
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 4, p 2150 (2024)
Minimal residual disease (MRD) is of major importance in onco-hematology, particularly in acute myeloid leukemia (AML). MRD measures the amount of leukemia cells remaining in a patient after treatment, and is an essential tool for disease monitoring,
Externí odkaz:
https://doaj.org/article/f7d67bfbe52248c286404e41f6738275
Publikováno v:
Diagnostics
Diagnostics, Vol 11, Iss 1982, p 1982 (2021)
Diagnostics, Vol 11, Iss 1982, p 1982 (2021)
The pathophysiology of myelodysplastic syndromes (MDSs) is complex and often includes immune dysregulation of both the innate and adaptive immune systems. Whereas clonal selection mainly involves smoldering inflammation, a cellular immunity dysfuncti
Autor:
Alexis Piedrafita, François Vergez, Julie Belliere, Nais Prades, Magali Colombat, Antoine Huart, Jean-Baptiste Rieu, Stéphanie Lagarde, Arnaud Del Bello, Nassim Kamar, Dominique Chauveau, Camille Laurent, Lucie Oberic, Loïc Ysebaert, David Ribes, Stanislas Faguer
Publikováno v:
Journal of Clinical Medicine, Vol 11, Iss 3, p 604 (2022)
Large granular T-cell leukemia is a clonal hematological condition often associated with autoimmune disorders. Whether small-sized T-cell clones that are otherwise asymptomatic can promote immune kidney disorders remains elusive. In this monocentric
Externí odkaz:
https://doaj.org/article/8818cbf78f84423587d37ac3457ed78f
Publikováno v:
Diagnostics, Vol 11, Iss 11, p 1982 (2021)
The pathophysiology of myelodysplastic syndromes (MDSs) is complex and often includes immune dysregulation of both the innate and adaptive immune systems. Whereas clonal selection mainly involves smoldering inflammation, a cellular immunity dysfuncti
Externí odkaz:
https://doaj.org/article/eafaa3a4705946218f780915a470f3a7
Autor:
Jean Philippe Vial, Nicolas Lechevalier, Francis Lacombe, Pierre-Yves Dumas, Audrey Bidet, Thibaut Leguay, François Vergez, Arnaud Pigneux, Marie C. Béné
Publikováno v:
Cancers, Vol 13, Iss 4, p 629 (2021)
The assessment of minimal residual disease (MRD) is increasingly considered to monitor response to therapy in hematological malignancies. In acute myeloblastic leukemia (AML), molecular MRD (mMRD) is possible for about half the patients while multipa
Externí odkaz:
https://doaj.org/article/6242daf37db64d71bc57318f500920ff
Autor:
Pierre-Yves Dumas, Sarah Bertoli, Emilie Bérard, Laetitia Largeaud, Audrey Bidet, Eric Delabesse, Thibaut Leguay, Harmony Leroy, Noémie Gadaud, Jean Baptiste Rieu, Jean-Philippe Vial, François Vergez, Nicolas Lechevalier, Isabelle Luquet, Emilie Klein, Audrey Sarry, Anne-Charlotte de Grande, Arnaud Pigneux, Christian Récher
Publikováno v:
Cancers, Vol 12, Iss 8, p 2044 (2020)
Two recent phase 3 trials showed that outcomes for relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML) patients may be improved by a single-agent tyrosine kinase inhibitor (TKI) (i.e., quizartinib or gilteritinib). In the current stud
Externí odkaz:
https://doaj.org/article/2297740205f7448ca90846c7539913b9
Autor:
Nizar Serhan, Pierre-Luc Mouchel, Philippe de Medina, Gregory Segala, Aurélie Mougel, Estelle Saland, Arnaud Rives, Antonin Lamaziere, Gaëtan Despres, Jean-Emmanuel Sarry, Clément Larrue, François Vergez, Laetitia Largeaud, Michel Record, Christian Récher, Sandrine Silvente-Poirot, Marc Poirot
Publikováno v:
Cancers, Vol 12, Iss 7, p 1725 (2020)
Dendrogenin A (DDA) is a mammalian cholesterol metabolite that displays potent antitumor properties on acute myeloid leukemia (AML). DDA triggers lethal autophagy in cancer cells through a biased activation of the oxysterol receptor LXRβ, and the in
Externí odkaz:
https://doaj.org/article/45b994b3ab9e49b49d353fd6cf9d60f9
Autor:
François Vergez, Marie-Laure Nicolau-Travers, Sarah Bertoli, Jean-Baptiste Rieu, Suzanne Tavitian, Pierre Bories, Isabelle Luquet, Véronique De Mas, Laetitia Largeaud, Audrey Sarry, Françoise Huguet, Eric Delabesse, Emilie Bérard, Christian Récher
Publikováno v:
Cancers, Vol 12, Iss 5, p 1174 (2020)
The prognostic impact of immunophenotypic CD34+CD38−CD123+ leukemic stem cell (iLSC) frequency at diagnosis has been demonstrated in younger patients treated by intensive chemotherapy, however, this is less clear in older patients. Furthermore, the
Externí odkaz:
https://doaj.org/article/53a06022de964ed586d15c242e5253f4
Autor:
Sarah Bertoli, Pierre-Yves Dumas, Emilie Bérard, Laetitia Largeaud, Audrey Bidet, Eric Delabesse, Suzanne Tavitian, Noémie Gadaud, Thibaut Leguay, Harmony Leroy, Jean-Baptiste Rieu, Jean-Philippe Vial, François Vergez, Nicolas Lechevalier, Isabelle Luquet, Emilie Klein, Audrey Sarry, Anne-Charlotte De Grande, Christian Récher, Arnaud Pigneux
Publikováno v:
Cancers, Vol 12, Iss 4, p 773 (2020)
A recent phase 3 trial showed that the outcome of patients with relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML) improved with gilteritinib, a single-agent second-generation FLT3 tyrosine kinase inhibitor (TKI), compared with stand
Externí odkaz:
https://doaj.org/article/0432c07aaaf441ce82c72c58d85291af